C2N Diagnostics logo

C2N Diagnostics

Fierce Medtech named C2N one of its Fierce 15 for 2020; "one of the most promising private companies in the industry.”

92 employees · est. 2007 · United States

VS
Hemosure® logo

Hemosure®

The #1 iFOB Test in the US.

25 employees · est. 2003 · Irwindale, United States

Hemosure® is the older company (2007 vs 2003); C2N Diagnostics is the larger of the two.

Side-by-Side Comparison

C2N Diagnostics Hemosure®
Founded
2007 2003 older
Headquarters
United States Irwindale, United States
Employees
92 larger 25
Industry
Biotechnology Food and Beverage, Manufacturing
Funding Stage
Corporate Round Not tracked yet
Total Funding
$52.20M Not tracked yet
Funding Rounds
4 Not tracked yet
Services
Not tracked yet Not tracked yet
Target Customers
Not tracked yet Not tracked yet
Taxonomy
Medtech, Diagnostics, Therapeutic Discovery, Neurological Disorders, Blood Tests, Alzheimer’s Disease, Precision Medicine, Mass Spectrometry, Health Care, FDA Breakthrough Device, CE Mark, Protein Diagnostics, Neurodegeneration, Research And Development Clinical Diagnostic Test Kits, FDA Cleared, Automated Immunochemical Fecal Occult Blood Diagnostic System, Healthcare Efficiency, Gastrointestinal Disorders, Rapid Diagnostics, Medical Diagnostics, Quality Of Life Improvement, Los Angeles Proximity, Medical Institutions Collaboration
Website
c2ndiagnostics.com hemosure.com
C2N Diagnostics logo

About C2N Diagnostics

C2N Diagnostics, established in 2007 and headquartered in the United States, is a biotechnology startup making significant strides in the medical industry. The company's dedication to innovation and excellence has been acknowledged by Fierce Medtech, which named C2N one of its Fierce 15 for 2020, re...

Hemosure® logo

About Hemosure®

Hemosure® Inc. has been leading the field of clinical diagnostic test kits and medical devices since 2003. The company prides itself on the enduring success of its Fecal Occult Blood test (iFOB), maintaining its position as the #1 test in the US for nearly a decade, showcasing its quality and effect...

We will tell you when either one moves

BounceWatch watches C2N Diagnostics and Hemosure® for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at C2N Diagnostics and Hemosure® — by email.

Frequently Asked Questions

C2N Diagnostics — Fierce Medtech named C2N one of its Fierce 15 for 2020; "one of the most promising private companies in the industry.”. Hemosure® — The #1 iFOB Test in the US. . Both companies operate in related markets but may differ in funding stage, team size, and product focus.
C2N Diagnostics has raised $52.20M while Hemosure® has raised undisclosed funding.
C2N Diagnostics and Hemosure® operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare C2N Diagnostics with someone else

Start typing a company name or domain.

Related Comparisons

Compiled from the BounceWatch company index. We last looked at C2N Diagnostics on 12 Sep 2024, and Hemosure® on 12 Sep 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy